GFAP and Alzheimer disease: For instance, Palmqvist et al. reported combining plasma p-tau217 with measurement of memory and executive function showed higher accuracy in predicting AD clinical diagnosis within 4 years.46 Stevenson-Hoare et al. predicted AD clinical diagnosis by combining Aβ40 or Aβ42, p-tau217, GFAP, NfL, APOE-ԑ4 and PRS and obtained an area under the curve (AUC) of 0.81.47 Binette et al. reported in an MCI population combination of p-tau217, HVA, APOE genotype, and cognition as predictors were able to discriminate progression to AD dementia at AUC of 0.89.48